Company intelligence / Profile preview

Novoprotein

Ownership: Private
Development stage: Commercial

Overview

Novoprotein is an established commercial supplier of recombinant proteins and related biotechnologies with over 10 years of experience. The company provides raw materials and technical solutions to the biopharmaceutical industry for vaccine development (including mRNA vaccines), molecular diagnostics, gene/cell therapy R&D; it does not develop its own clinical-stage therapeutics but supports those who do.

Therapeutic areas: OtherHematologyRare DiseasesInfectious Diseases
Modalities: Recombinant proteinProteinEnzymeAntibodymRNA-based drugs (as a service provider)
Industry: Chemicals & Materials

Partnerships

Serves broad industry clients in biopharma R&D/manufacturing

Beyond the preview

Go deeper on Novoprotein.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novoprotein.

Explore the full profile